US 12,234,265 B2
Stabilized RSV F proteins and uses thereof
Lan Zhang, Chalfont, PA (US); Arthur Fridman, Lake Ariel, PA (US); Eberhard Durr, Quakertown, PA (US); and Andrew Bett, Lansdale, PA (US)
Assigned to Merck Sharp & Dohme LLC, Rahway, NJ (US)
Filed by Merck Sharp & Dohme LLC, Rahway, NJ (US)
Filed on Dec. 20, 2022, as Appl. No. 18/068,867.
Application 18/068,867 is a continuation of application No. 16/964,118, granted, now 11,566,051, previously published as PCT/US2019/014873, filed on Jan. 24, 2019.
Claims priority of provisional application 62/623,184, filed on Jan. 29, 2018.
Prior Publication US 2023/0141153 A1, May 11, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/135 (2006.01); A61K 39/155 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 14/135 (2013.01) [A61K 39/155 (2013.01); C12N 7/00 (2013.01); A61K 2039/54 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/55555 (2013.01); C12N 2760/18534 (2013.01)] 11 Claims
 
1. A recombinant respiratory syncytial virus (RSV) F protein trimer, comprising:
an amino acid sequence set forth in SEQ ID NOs: 26 or 27 and a pharmaceutically acceptable excipient.